Moderna on Wednesday said its combination vaccine targeting Covid and the flu will move to a final stage trial after showing positive results in an earlier study.
The biotech company is hoping its shot, mRNA-1083, can win approval from regulators in 2025.
A large study from Singapore suggests that COVID-19 infection increased the risk of new-onset cardiovascular and cerebrovascular complications during the Delta variant era and that vaccination lowered the risk.
Recent Comments